{'fraction_non_alphanumeric': 0.03983516483516483, 'fraction_numerical': 0.024725274725274724, 'mean_word_length': 5.024793388429752, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Poseidonol in the treatment of hyperlipidemia in patients with type 2 diabetes mellitus].

Thirty five patients with type 2 diabetes mellitus complicated by cardiovascular diseases received 6-month treatment for hyperlipidemia with poseidonol that represents a set of essential polyunsaturated fatty acids. This yielded good results as 11.6%-, 30%- and 24.2% decreases in the levels of cholesterol, triglycerides, and beta-lipoprotein, respectively, and a 9.9%- increase in alpha-lipoprotein. Lipid metabolism became normal in 34.2% of the patients, the remaining had positive changes as normalization of 1 to 3 lipid parameters. The tolerance of the agent was good, no negative effect on hepatic and renal functions was found.